Contact CFFC


Clinical Trial Alerts – August 2021

The following clinical trial alerts were issued by Cystic Fibrosis Foundation in August 2021.

August 2, 2021

Study to evaluate inhaled AR-501 in healthy adults and adults with cystic fibrosis and Pseudomonas aeruginosa

Status: Enrolling

Description: This study is testing inhaled AR-501, a drug intended to treat infections in the lung. The study will measure the drug’s safety, how well it works, and how the body processes it. Multiple doses of AR-501 will be tested in both healthy adults and adults with cystic fibrosis who are infected with Pseudomonas aeruginosa to find the best dose.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 45% or greater

Number of Visits: 11

Length of Participation: 6 weeks link:

August 23, 2021

Study to evaluate VX-121 in adults 18 years and older with cystic fibrosis

Status: Completed with results

Description: This study evaluated the safety, tolerability, and effectiveness of three different doses of the drug VX-121 in triple combination with tezacaftor (TEZ) and VX-561 (deuterated ivacaftor) in people with cystic fibrosis who have two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.

Age: 18 Years and Older

Mutation: Two Copies F508del or One Copy F508del

Fev1% Predicted: 40 to 90%

Number of Visits: 10

Length of Participation: 17 weeks link:

Comments are closed.